#United States #Lexington #NSCLC #Zenocutuzumab #NRG1 Fusion

Continued Benefits of Zenocutuzumab Treatment in NRG1 Positive Non-Small Cell Lung Cancer Patients

Introduction

Recent findings from the eNRGy trial highlight the promising outcomes of zenocutuzumab treatment for patients diagnosed with advanced neuregulin 1 (NRG1) fusion-positive non-small cell lung cancer (NSCLC). Presented during the 2026 IASLC Targeted Therapies of Lung Cancer meeting, these results demonstrate the potential of continuing treatment even after traditional progression markers. This article delves into the trial's insights, implications for treatment approaches, and the versatility of zenocutuzumab in managing such challenging cases.

The Challenge of NRG1+ NSCLC

NRG1-positive NSCLC is notorious for its poor treatment response and limited options as patients reach the progression phase of their disease. Traditional non-targeted therapies have proven ineffective for a majority of these patients, necessitating innovative solutions. Dr. Misako Nagasaka from the University of California, Irvine emphasized, "Patients suffering from advanced stages of NRG1 fusion-positive NSCLC often have limited prospects after their disease progresses."

The eNRGy Trial Analysis

In this post hoc analysis, a total of 27 patients were evaluated who had received at least three doses of zenocutuzumab following radiographic progression. Notably, 81% of the participants exhibited oligoprogression, while 19% demonstrated diffuse disease progression. Following their treatment course, the median exposure to zenocutuzumab significantly increased, showcasing its viability even as the disease evolved.

Among these patients, eight managed to continue their treatment for over six months post-progression, including one individual who has been on therapy for more than 23 months beyond progression and continues to receive it as of December 2025. Another patient persisted on treatment for nearly four years total.

Additionally, a remarkable 22% were able to keep on with zenocutuzumab after localized management of progressing lesions, utilizing various methods such as radiotherapy and surgical interventions. Crucially, the treatment was well-tolerated by patients, with no therapy interruptions due to adverse effects.

Insights on Treatment Beyond Progression

The data from this trial strongly suggest that disease progression may not uniformly lead to futile treatment scenarios. Pritesh J. Gandhi from Partner Therapeutics pointed out that the analyses revealed the significant diversity of disease characteristics at the point of progression. He noted that continuing targeted therapy like zenocutuzumab might yield crucial benefits without raising new safety concerns.

Regulatory Approval and Future Implications

In December 2024, the FDA granted zenocutuzumab-zbco (commercially known as BIZENGRI®) accelerated approval for use in adult patients with advanced unresectable or metastatic NSCLC and pancreatic adenocarcinoma, both harboring NRG1 gene fusions. This designation underscores the evidence supporting the efficacy and response duration of zenocutuzumab in managing these specific cancer types. However, ongoing trials are essential to further validate and describe the clinical benefits experienced by patients using this breakthrough therapy.

Conclusion

The revelations from the eNRGy trial mark a potential turning point in the management of NRG1-positive NSCLC, highlighting the importance of targeted therapy in extending treatment efficacy even after traditional progression. As further studies continue and real-world evidence builds, zenocutuzumab offers hope to patients who previously faced troubling prognoses, paving the way for more personalized and effective oncology treatments.

For more detailed results from the eNRGy trial and insights into the use of zenocutuzumab-zbco, visit Partner Therapeutics.